trial

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

NCTId NCT01900522
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 76 (estimated)
Sponsored by Takeda
Primary completion 2014-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
76 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-07
Primary completion
2014-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
ITI-214 Dose AITI-214 Dose BITI-214 Dose CITI-214 Dose D (Elderly)ITI-214 Dose EITI-214 Dose FITI-214 Dose GITI-214 Dose H

Sponsors

TakedaLead Sponsor
Intra-Cellular Therapies, Inc.Collaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
76
Phase
PHASE1
Primary Completion Date
2014-09
Status
TERMINATED
relationships
The graph out of here
drug
ITI-214 Dose A
drug
ITI-214 Dose B
drug
ITI-214 Dose C
drug
ITI-214 Dose D (Elderly)
drug
ITI-214 Dose E
drug
ITI-214 Dose F
drug
ITI-214 Dose G
drug
ITI-214 Dose H
drug
lead_sponsor
Takeda
company
collaborator
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication